Tarsus Pharmaceuticals, Inc. (TARS)
NASDAQ: TARS · Real-Time Price · USD
59.85
+2.16 (3.74%)
At close: Jul 17, 2026, 4:00 PM EDT
60.90
+1.05 (1.75%)
After-hours: Jul 17, 2026, 5:14 PM EDT
Tarsus Pharmaceuticals Stock Forecast
Stock Price Forecast
According to 9 analysts polled by S&P Global, Tarsus Pharmaceuticals stock has a consensus rating of "Strong Buy" and an average price target of $94.56. The average 1-year stock price forecast is 57.99% higher than the current stock price, while the lowest is $88 (+47.03%) and the highest is $104 (+73.77%).
Price Target: $94.56 (+57.99%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Tarsus Pharmaceuticals stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Feb '26 | Mar '26 | Apr '26 | May '26 | Jun '26 | Jul '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 7 | 8 | 8 | 8 | 8 | 8 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 9 | 9 | 9 | 9 | 9 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Mizuho Securities | Mizuho Securities | Buy Maintains $100 | Buy | Maintains | $100 | +67.08% | Jul 14, 2026 |
| William Blair | William Blair | Buy Maintains n/a | Buy | Maintains | n/a | n/a | Jul 14, 2026 |
| LifeSci Capital | LifeSci Capital | Buy Reiterates $95 | Buy | Reiterates | $95 | +58.73% | Jul 13, 2026 |
| Guggenheim | Guggenheim | Buy Reiterates $90 | Buy | Reiterates | $90 | +50.38% | Jul 13, 2026 |
| Barclays | Barclays | Buy Maintains $100 | Buy | Maintains | $100 | +67.08% | Jul 10, 2026 |
Financial Forecast
Revenue This Year
712.64M
from 451.36M
Increased by 57.89%
Revenue Next Year
900.30M
from 712.64M
Increased by 26.33%
EPS This Year
-2.25
from -1.59
EPS Next Year
1.66
from -2.25
EPS and Forward PE are based on non-GAAP adjusted numbers.